Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Neurocrine Biosciences will present new two-year clinical data for CRENESSITY (crinecerfont) at the ENDO 2026 meeting, highlighting sustained androgen control and glucocorticoid dose reduction in classic CAH patients. The data from the CAHtalyst program covers both adult and pediatric populations, demonstrating long-term benefits in metabolic health, bone health, and quality of life, reinforcing CRENESSITY as the emerging standard of care.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Adult study n
- 182
- Study duration
- 2 years
- Total program n
- 285
- Pediatric study n
- 103
- Vykat xr withdrawal period
- 16 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.